NCT03385239: A reported trial by Akcea Therapeutics
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03385239 |
|---|---|
| Title | A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 678354 Administered Subcutaneously to Patients With Hypertriglyceridemia and Established Cardiovascular Disease (CVD) or at a High Risk for CVD |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 30, 2018 |
| Completion date | Nov. 25, 2019 |
| Required reporting date | Nov. 25, 2022, midnight |
| Actual reporting date | Nov. 19, 2022 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |